Drugs / JS009
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05650203 | Mar 2023 → Oct 2025 | cancer-related condition | Shanghai Junshi Bioscience Co., Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05650203 ↗ |
| Route | Intravenous | “JS009,18mg/60mg/180mg/600mg/1200mg, JS006, fixed dose 600mg, Toripalimab injection fixed dose 240mg,IV infusion, every 3 weeks (q3w).” NCT05650203 ↗ |